🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Metformin Effects According to SLC16A11 Carrier Status

Recruitingn/aAges 18 Years - 65 YearsAllInstituto Nacional de Ciencias Medicas y Nutricio…
NCT07760883 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective observational study will evaluate whether the SLC16A11 risk variant influences the response to metformin in adults with type 2 diabetes. Participants will be classified as carriers or noncarriers and followed for 6 months while receiving extended-release metformin titrated to the maximum tolerated dose, between 1,500 and 2,250 mg/day. The primary outcome is the change in glycated hemoglobin, with additional assessment of seven-point capillary glucose profiles, liver enzymes, visceral fat, lipid profile, and lactate concentrations. The study plans to include 154 participants to compare treatment response between both genetic groups and explore the potential value of a more personalized therapeutic approach.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Male and female participants * Aged 18 to 65 years * Diagnosis of type 2 diabetes * Estimated glomerular filtration rate (eGFR) \>60 mL/min * Glycated hemoglobin (HbA1c) ≤8% * Participants who are treatment-naïve, receiving metformin monotherapy, or receiving dual glucose-lowering therapy * Participants who agree to take part in the study Exclusion Criteria: * Participants receiving treatment with three glucose-lowering medications * Participants receiving insulin therapy * Pregnancy * Breastfeeding * Chronic conditions such as HIV infection, cancer, or rheumatologic diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) * Body mass index (BMI) ≥45 kg/m² * Concurrent participation in another research study
💊

What it tests

  • Not listed
📍

Where

1 site
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy